Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
c-Jun N-terminal kinases (JNKs) are MAP kinase family members that become highly activated after cells are exposed to stress conditions and are poorly activated by exposure to growth factors or mitogens. JNK inhibitor XVI is a selective, irreversible JNK inhibitor (IC50s = 4.67, 18.7, and 0.98 nM for JNK1, 2, and 3, respectively) that prevents phosphorylation of c-Jun in A375 and HeLa cells with EC50 values of 338 and 486 nM, respectively.1 It has been shown to inhibit JNK kinase activity by a mechanism that depends on covalent modification of cysteine116 in the ATP-binding motif.1 This compound has been used to explore the role of JNK in mediating cancer cell death.2,3
WARNING This product is not for human or veterinary use.
1. Discovery of potent and selective covalent inhibitors of JNK. Chem. Biol. 19(1), 140-154 (2012).
2. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. Biochem. Biophys. Res. Commun. 440(4), 701-706 (2013).
3. Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-